1)所 敬:屈折・調節の基礎と臨床強度近視の眼軸延長機転と網膜脈絡膜萎縮.日眼会誌 98:1213-1237,1994
2)大野京子:近視性網脈絡膜萎縮・近視性脈絡膜新生血管・後部強膜ぶどう腫.眼科 98:1213-1237,1994
3)Tano Y:Pathologic myopia:where are we now? Am J Ophthalmol 134:645-660, 2002
4)Avila MP, Weiter JJ, Jalkh AE et al:Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91:1573-1581, 1984
5)Hamelin N, Glacet-Bernard A, Brindeau C et al:Long-term visual outcome of choroidal neovascularization in pathologic myopia. Surgical treatment of subfoveal neovascularization in myopia:macular translocation vs surgical removal. Am J Ophthalmol 133:530-536, 2002
6)Tsujikawa M, Tsujikawa K, Lewis JM et al:Change in retinal sensitivity due to excision of choroidal neovascularization and its influence on visual acuity outcome. Retina 19:135-140, 1999
7)Verteporfin in Photodynamic Therapy(VIP)Study Group:Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin:1-year results of a randomized clinical trial. VIP Report 1. Ophthalmology 108:841-852, 2001
8)Blinder KJ, Blumenkranz MS, Bressler NM et al:Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia. 2-year results of a randomized clinical trial. VIP report No. 3. Ophthalmology 110:667-673, 2003
9)Sakaguchi H, Ikuno Y, Gomi F et al:Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91:161-165, 2007
10)Chan WM, Lai TY, Lai RY et al:Intravitreal bevacizumab(Avastin)for myopic choroidal neovascularization. Six-month results of a prospective pilot study. Ophthalmology 114:2190-2196, 2007
11)Yoshida T, Ohno-Matsui K, Ichinose S et al:Myopic choroidal neovascularization:a 10-year follow-up. Ophthalmology 110:1297-1305, 2003
12)Virgili G, Varano M, Giacomelli G et al:Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia. Am J Ophthalmol 143:77-82, 2007
13)Lam DS, Chan WM, Liu DT et al:Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes:a prospective series of 1 and 2 year follow up. Br J Ophthalmol 88:1315-1319, 2004
14)Ergun E, Heinzl H, Stur M:Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 138:434-438, 2004
15)Bressler NM, Arnold J, Benchaboune M et al:Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration:additional information regarding baseline lesion composition's impact on vision outcomes. TAP report No. 3. Arch Ophthalmol 120:1443-1454, 2002
16)Blinder KJ, Bradley S, Bressler NM et al:Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration:TAP and VIP report No. 1. Am J Ophthalmol 136:407-418, 2003
17)Parodi MB, Da Pozzo S, Ravalico G:Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia. Acta Ophthalmol Scand 85:50-54, 2007
18)Wachtlin J, Behme T, Heimann H et al:Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 241:518-521, 2003
19)Postelmans L, Pasteels B, Coquelet P et al:Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 138:803-808, 2004